Compare PRDO & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRDO | ANIP |
|---|---|---|
| Founded | 1994 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | PRDO | ANIP |
|---|---|---|
| Price | $31.62 | $86.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $42.00 | ★ $107.33 |
| AVG Volume (30 Days) | 511.5K | ★ 553.0K |
| Earning Date | 02-17-2026 | 02-27-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 17.26 | N/A |
| EPS | ★ 2.33 | 1.67 |
| Revenue | $810,888,000.00 | ★ $826,880,000.00 |
| Revenue This Year | $26.43 | $44.37 |
| Revenue Next Year | $3.65 | $9.83 |
| P/E Ratio | ★ $13.57 | $51.21 |
| Revenue Growth | 24.23 | ★ 48.87 |
| 52 Week Low | $23.87 | $54.10 |
| 52 Week High | $38.03 | $99.50 |
| Indicator | PRDO | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 60.71 | 58.89 |
| Support Level | $30.84 | $83.03 |
| Resistance Level | $32.02 | $87.07 |
| Average True Range (ATR) | 0.80 | 3.33 |
| MACD | 0.07 | 0.88 |
| Stochastic Oscillator | 80.88 | 91.10 |
Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segments include the American InterContinental University, the University of St. Augustine for Health Sciences, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services, with the majority of the students enrolled in programs offered fully online. The majority of the company's revenue comes from the Colorado Technical University segment.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.